Lantheus Holdings Contact | Compliance | Reimbursement | Supply Updates | Supplier Link
Investor Relations

A HERITAGE OF INNOVATION AND LEADERSHIP

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“Lantheus”), which is a global leader in developing, manufacturing, selling and distributing innovative diagnostic image agents and products.

Our expertise in discovering, developing and commercializing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease. Lantheus has a rich heritage and expertise in cardiovascular imaging and nuclear medicine, having pioneered many of the most significant products used in medical imaging.

Our current imaging agents primarily assist in the diagnosis of heart, vascular and other diseases using nuclear imaging, echocardiography and magnetic resonance imaging (MRI) technologies. We have a pipeline of next-generation and first-in-class products using Positron Emission Tomography (PET) and MRI technologies.

Our vision is to be the leading provider of innovative medical imaging solutions to improve human life. We are committed to developing next generation and first-in-class imaging agents to assist physicians in the diagnosis of heart, vascular and other diseases.

With direct operations in the United States, Puerto Rico, Canada and Australia, we have a long and distinguished history of developing and commercializing innovative market-changing products.

Recent News

LANTHEUS HOLDINGS ANNOUNCES DIVESTITURE OF ITS CANADIAN RADIOPHARMACY OPERATIONS AND COMMENCEMENT OF LONG-TERM SUPPLY AGREEMENT

Transaction Simplifies Distribution Model in Canada and Improves Operational Efficiencies

NORTH BILLERICA, Mass. (January 13, 2016)Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products, today announced the sale of its radiopharmacies and Gludef® (Fludeoxyglucose F18 Injection)  manufacturing and distribution business in Canada to Isologic Innovative Radiopharmaceuticals Ltd. (“Isologic”) for U.S. $9.0 million in cash, subject to certain purchase price adjustments. As part of the transaction, the Company and Isologic also entered into a long-term supply contract under which the Company will supply Isologic with the Company’s products on commercial terms and under which Isologic has agreed to certain product purchase commitments.  

click here for the press release

Company Spotlight

Webcast Image

Webcast
24th Annual Credit Suisse Healthcare Conference Call
(Live)
Wednesday, November 11, 2015 at 10:30 a.m. ET, 8:30 a.m. MT

Webcast Image

Webcast
Q3 2015 Lantheus Holdings Earnings Conference Call
(Live)
Wednesday, November 4, 2015 at 4:30 p.m. ET

 

© 2015 Lantheus Medical Imaging, Inc. Contact | Compliance | Reimbursement | Supply Updates | Supplier Link | Site Map